Ocugen, Inc. (OCGN) is a clinical-stage biopharmaceutical company in the Biotechnology sector focused on gene therapies for blindness diseases. Its core business activities are Shariah-compliant, emphasizing medical innovation for unmet needs. However, the financial screening reveals a critical failure in the interest income ratio at 111.72%, far exceeding the 5% threshold across all standards, driven by low revenue and interest-bearing cash holdings. Debt and liquidity ratios are strong at 10.41% and 12.37%, respectively. The company is not included in any major Shariah indices, leading to an overall NON_COMPLIANT status with a B quality rating.